Synergistic Interaction between Cyclophosphamide or Paclitaxel and the Bioreductive Compound NLCPQ-1, In Vivo

Oncology Research

Volumn 13, Issue 12, 2002, Pages 561-566

  Papadopoulou, M V ^a   Ji, M ^a   Bloomer, W D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Bioreductive drugs; Chemotherapeutic agents; NLCPQ 1; Potentiation

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; 9 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO]CYCLOPENTENO[B]QUINOLINE; CYCLOPHOSPHAMIDE; NSC 709257; PACLITAXEL; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CELL KILLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ASSAY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL;

EID: 0842327344     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000003108748081     Document Type: Article

References (28)

1. Hockel, M.; Schlenger, K.; Mitze, M.; Schaffer, U.; Vaupel, P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6:3-9; 1996.
2. Siemann, D. W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 10:1585-1594; 1984.
3. Grau, C.; Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. 13:301-309; 1988.
4. Brown, J. M. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol. Med. Today 6(4): 157-162; 2000.
5. Stratford, I. J.; Workman, P. Bioreductive drugs into the next millennium. Anticancer Drug Design 13:519-528; 1998.
6. Langmuir, V. K.; Rooker, J. A.; Osen, M.; Mendonca, H. L.; Laderoute, K. R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res. 54:2845-2847; 1994.
7. Siemann, D. W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother. Oncol. 34:47-53; 1995.
8. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49-58; 1996.
9. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-l-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol. Res. 9:249-257; 1997.
10. Dorie, M. J.; Brown, J. M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol. 39:361-366; 1997.
11. Gallagher, R.; Hughes, C. M.; Murray, M. M.; Friery, O. P.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br. J. Cancer 85:625-629; 2001.
12. Papadopoulou, M. V.; Ji, M.; Ji, X.; Bloomer, W. D. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo. Comparison with tirapazamine. Cancer Chem. Pharmacol. 50:291-298; 2002.
13. Papadopoulou, M. V.; Ji, M.; Ji, X.; Bloomer, W. D. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo. Comparison with tirapazamine. Oncol. Res. 13:47-54; 2002.
14. Papadopoulou, M. V.; Ji, M.; Ji, X.; Bloomer, W. D.; Hollingshead, M. G. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem. Pharmacol. 50:501-508; 2002.
15. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D.; Hollingshead, M. G. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J. Exp. Ther. Oncol. 2(5):298-305; 2002
16. Miller, V. A.; Ng, K. K.; Grant, S. C.; Kindler, H.; Pizzo, B.; Heelan, R. T.; von Roemeling, R.; Kris, M. G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 8:1269-1271; 1997.
17. Treat, J.; Johnson, E.; Langer, C.; Belani, C.; Haynes, B.; Greenberg, R.; Rodriquez, R.; Drobins, P.; Miller, W.; Meehan, L., Jr.; McKeon, A.; Devin, J.; von Roemeling, R.; Viallet, J. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase 11 study. J. Clin. Oncol. 16:3524-27; 1998.
18. von Pawel, J.; von Roemeling, R.; Gatzemeier, U.; Boyer, M.; Elisson, L. O.; Clark, P.; Talbot, D.; Rey, A.; Butler, T. W.; Hirsh, V.; Olver, I.; Bergman, B.; Ayoub, J.; Richardson, G.; Dunlop, D.; Arcenas, A.; Vescio, R.; Viallet, J.; Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol. 18:1351-1359; 2000.
19. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 12:185-192; 2000.
20. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-l-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol. Res. 8:425-434; 1996.
21. Papadopoulou, M. V.; Rosenzweig, H. S.; Ji, M.; Khan, S. H.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as as chemosensitizer: Mechanistic studies. II. Oncol. Res. 10:163-173; 1998.
22. Rockwell, S. C.; Kallman, R. F.; Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49:735; 1972.
23. Siemann, D. W.; Allalunis-Turner, M. J. Potentiation of combination chemotherapy by nitroheterocyclics. Int. J. Radiat. Oncol. Biol. Phys. 16:973-976; 1988.
24. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother. Pharmacol. 48(2):160-168; 2001.
25. Papadopoulou, M. V.; Ji, X.; Bloomer, W. D. Mechanisms involved in the potentiation of paclitaxel or 5-FU by the hypoxic cytotoxin NLCQ-1. Clin. Cancer Res. Suppl. 7(11):3679; 2001.
26. McGuire, W. P.; Rowinsky, E. K.; Rosenshine, N. B.; Grumbine, F. C.; Ettingger, D. S.; Armstrong, D. K.; Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111:273-279; 1989.
27. Etlinger, D. S. Overview of paclitaxel (taxol) in advanced lung cancer. Semin. Oncol. 20:46-49; 1993.
28. Forastiere, A. A. Use of paclitaxel (taxol) in squamous cell carcinoma of the head and neck. Semin. Oncol. 20:56-60; 1993.